| __timestamp | Merus N.V. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 5078000000 |
| Thursday, January 1, 2015 | 839656 | 4717000000 |
| Friday, January 1, 2016 | 4478145 | 5096000000 |
| Sunday, January 1, 2017 | 16432324 | 4986000000 |
| Monday, January 1, 2018 | 11890871 | 4214000000 |
| Tuesday, January 1, 2019 | 34110000 | 3806000000 |
| Wednesday, January 1, 2020 | 35781000 | 3671000000 |
| Friday, January 1, 2021 | 40896000 | 3528000000 |
| Saturday, January 1, 2022 | 52200000 | 3445000000 |
| Sunday, January 1, 2023 | 59836000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unveiling the hidden dimensions of data
In the pharmaceutical industry, strategic spending on Selling, General, and Administrative (SG&A) expenses can significantly impact a company's market position. Over the past decade, Teva Pharmaceutical Industries Limited and Merus N.V. have demonstrated contrasting SG&A spending patterns.
Teva, a global leader, has consistently allocated substantial resources to SG&A, averaging around $4.2 billion annually. However, a noticeable decline of approximately 31% from 2014 to 2023 suggests a strategic shift towards cost optimization.
Conversely, Merus, a smaller player, has seen its SG&A expenses skyrocket by over 1,400% during the same period, reflecting its aggressive growth strategy and market expansion efforts.
These divergent paths highlight the varied approaches companies take in navigating the competitive pharmaceutical landscape, with Teva focusing on efficiency and Merus on expansion.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Genmab A/S
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Alkermes plc vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and Merus N.V.
Comparing SG&A Expenses: MorphoSys AG vs Merus N.V. Trends and Insights
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.